Literature DB >> 15815895

Randomised controlled trial comparing cisatracurium and vecuronium infusions in a paediatric intensive care unit.

Margarita Burmester1, Quen Mok.   

Abstract

OBJECTIVE: To evaluate and compare the efficacy, infusion rate and recovery profile of vecuronium and cisatracurium continuous infusion in critically ill children requiring mechanical ventilation. DESIGN AND
SETTING: Prospective, randomised, double-blind, single-centre study in critically ill children in a paediatric intensive care unit in a tertiary children's hospital.
METHODS: Thirty-seven children from 3 months to 16 years old (median 4.1 year) were randomised to receive either drug; those already receiving more than 6 h of neuromuscular blocking drugs were excluded. The Train-of-Four (TOF) Watch maintained neuromuscular blockade to at least one twitch in the TOF response. Recovery time was measured from cessation of infusion until spontaneous TOF ratio recovery of 70%.
RESULTS: The cisatracurium infusion rate in nineteen children averaged 3.9+/-1.3 microg kg(-1) min(-1) with a median duration of 63 h (IQR 23-88). The vecuronium infusion rate in 18 children averaged mean 2.6+/-1.3 microg kg(-1) min(-1) with a median duration of 40 h (IQR 27-72). Median time to recovery was significantly shorter with cisatracurium (52 min, 35-73) than with vecuronium (123 min, 80-480). Prolonged recovery of neuromuscular function (>24 h) occurred in one child (6%) on vecuronium.
CONCLUSIONS: Recovery of neuromuscular function after discontinuation of neuromuscular blocking drug infusion in children is significantly faster with cisatracurium than vecuronium. Neuromuscular monitoring was not sufficient to eliminate prolonged recovery in children on vecuronium infusions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15815895     DOI: 10.1007/s00134-005-2615-3

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  32 in total

1.  Anaphylactoid reactions after cisatracurium administration in six patients.

Authors:  J Krombach; N Hunzelmann; F Köster; A Bischoff; H Hoffmann-Menzel; W Buzello
Journal:  Anesth Analg       Date:  2001-11       Impact factor: 5.108

2.  [Cisatracurium--is the stereoisomer an "ideal" relaxant? Histamine liberation and tryptase determination after bolus administration of cistracurium: a comparison with vecuronium].

Authors:  J Soukup; A Doenicke; R Hoernecke; J qass
Journal:  Anaesthesist       Date:  1997-06       Impact factor: 1.041

3.  Cisatracurium during halothane and balanced anaesthesia in children.

Authors:  O A Meretoja; T Taivainen; K Wirtavuori
Journal:  Paediatr Anaesth       Date:  1996       Impact factor: 2.556

4.  Atracurium and status epilepticus?

Authors:  C A Manthous; W Chatila
Journal:  Crit Care Med       Date:  1995-08       Impact factor: 7.598

5.  A comparison of cisatracurium (51W89) and atracurium by infusion in critically ill patients.

Authors:  P J Newman; A C Quinn; R M Grounds; J M Hunter; A H Boyd; N B Eastwood; B J Pollard; A J Pearson; N J Harper; R J Beale; M Sutjarittam; J M Elliot; J F Bion
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

6.  A prospective evaluation of the continuous infusion of cis-atracurium for neuromuscular blockade in the pediatric intensive care unit patient: efficacy and dosage requirements.

Authors:  J D Tobias
Journal:  Am J Ther       Date:  1997 Sep-Oct       Impact factor: 2.688

7.  Agreement between muscle movement and peripheral nerve stimulation in critically ill pediatric patients receiving neuromuscular blocking agents.

Authors:  O Peña; S Prestjohn; C E Guzzetta
Journal:  Heart Lung       Date:  2000 Sep-Oct       Impact factor: 2.210

8.  The safety and efficacy of cisatracurium 0.15 mg.kg(-1) during nitrous oxide-opioid anaesthesia in infants and children.

Authors:  T Taivainen; G H Meakin; O A Meretoja; K Wirtavuori; R J Perkins; A K Murphy; G R Fisher; M R Waiter
Journal:  Anaesthesia       Date:  2000-11       Impact factor: 6.955

9.  Retrospective pharmacoeconomic evaluation of dosing vecuronium by peripheral nerve stimulation versus standard clinical assessment in critically ill patients.

Authors:  B J Zarowitz; M I Rudis; K Lai; A Petitta; M Lulek
Journal:  Pharmacotherapy       Date:  1997 Mar-Apr       Impact factor: 4.705

10.  Tachyphylaxis associated with continuous cisatracurium versus pancuronium therapy.

Authors:  Salmaan Kanji; Jeffrey F Barletta; James J Janisse; James A Kruse; John W Devlin
Journal:  Pharmacotherapy       Date:  2002-07       Impact factor: 4.705

View more
  2 in total

Review 1.  Year in review in intensive care medicine, 2005. III. Nutrition, pediatric and neonatal critical care, and experimental.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-18       Impact factor: 17.440

2.  Compared efficacy and tolerance of the neuromuscular blockade induced by brand-name (Nimbex®) and generic (Cisatrex®) of cisatracurium in mechanically ventilated critically ill patients: a crossover double-blind randomized study.

Authors:  Nesrine Fraj; Khaoula Meddeb; Abdelbaki Azouzi; Sana Romdhani; Helmi Ben Saad; Mohamed Boussarsar
Journal:  Pan Afr Med J       Date:  2020-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.